TheraRadar
← Back
Data updated: Jun 28, 2026

Humacyte Global Inc.

Biotech
Pharmaceuticals Execution: Good

Humacyte Global Inc. is a biotechnology company with 1 FDA-approved products.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)

Humacyte Global Inc.'s Key Drugs

Humacyte Global Inc.'s core commercial portfolio centers on symvess — its most strategically important drugs approved in the last 15 years.

symvess
Approved 2024

Humacyte Global Inc.'s Recent FDA Approvals

Humacyte Global Inc. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

symvess BLA
2024-12-18
acellular tissue engineered vessel-tyod
1 INDICATIONS AND USAGE SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. ( 1 )

Humacyte Global Inc.'s Therapeutic Areas

Disease areas where Humacyte Global Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

Humacyte Global Inc. Pipeline Snapshot

Active clinical trials for Humacyte Global Inc. across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • symvess leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/3 completed
  • • Speed: 85 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges